264 related articles for article (PubMed ID: 37417824)
1. Background Medical Therapy and Clinical Outcomes From the VICTORIA Trial.
Ezekowitz JA; McMullan CJ; Westerhout CM; Piña IL; Lopez-Sendon J; Anstrom KJ; Hernandez AF; Lam CSP; O'Connor CM; Pieske B; Ponikowski P; Roessig L; Voors AA; Koglin J; Armstrong PW; Butler J;
Circ Heart Fail; 2023 Sep; 16(9):e010599. PubMed ID: 37417824
[TBL] [Abstract][Full Text] [Related]
2. Beta-blockers and inhibitors of the renin-angiotensin aldosterone system for chronic heart failure with preserved ejection fraction.
Martin N; Manoharan K; Thomas J; Davies C; Lumbers RT
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD012721. PubMed ID: 29952095
[TBL] [Abstract][Full Text] [Related]
3. Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.
Teng TK; Tromp J; Tay WT; Anand I; Ouwerkerk W; Chopra V; Wander GS; Yap JJ; MacDonald MR; Xu CF; Chia YM; Shimizu W; ; Richards AM; Voors A; Lam CS
Lancet Glob Health; 2018 Sep; 6(9):e1008-e1018. PubMed ID: 30103979
[TBL] [Abstract][Full Text] [Related]
4. Blood Pressure and Safety Events With Vericiguat in the VICTORIA Trial.
Lam CSP; Mulder H; Lopatin Y; Vazquez-Tanus JB; Siu D; Ezekowitz J; Pieske B; O'Connor CM; Roessig L; Patel MJ; Anstrom KJ; Hernandez AF; Armstrong PW;
J Am Heart Assoc; 2021 Nov; 10(22):e021094. PubMed ID: 34743540
[TBL] [Abstract][Full Text] [Related]
5. Medical Therapy During Hospitalization for Heart Failure With Reduced Ejection Fraction: The VICTORIA Registry.
Greene SJ; Ezekowitz JA; Anstrom KJ; Demyanenko V; Givertz MM; Piña IL; O'Connor CM; Koglin J; Roessig L; Hernandez AF; Armstrong PW; Mentz RJ
J Card Fail; 2022 Jul; 28(7):1063-1077. PubMed ID: 35301107
[TBL] [Abstract][Full Text] [Related]
6. Optimal Pharmacologic Treatment of Heart Failure With Preserved and Mildly Reduced Ejection Fraction: A Meta-analysis.
Xiang B; Zhang R; Wu X; Zhou X
JAMA Netw Open; 2022 Sep; 5(9):e2231963. PubMed ID: 36125813
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of Pharmacologic and Cardiac Implantable Electronic Device Therapies in Patients With Heart Failure and Reduced Ejection Fraction: A Systematic Review and Network Meta-Analysis.
Tseng AS; Kunze KL; Lee JZ; Amin M; Neville MR; Almader-Douglas D; Killu AM; Madhavan M; Cha YM; Asirvatham SJ; Friedman PA; Gersh BJ; Mulpuru SK
Circ Arrhythm Electrophysiol; 2019 Jun; 12(6):e006951. PubMed ID: 31159582
[TBL] [Abstract][Full Text] [Related]
8. Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure.
Wirtz HS; Sheer R; Honarpour N; Casebeer AW; Simmons JD; Kurtz CE; Pasquale MK; Globe G
J Am Heart Assoc; 2020 Aug; 9(16):e015042. PubMed ID: 32805181
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Dosing of Medical Therapy for Heart Failure: From the CHAMP-HF Registry.
Greene SJ; Butler J; Hellkamp AS; Spertus JA; Vaduganathan M; Devore AD; Albert NM; Patterson JH; Thomas L; Williams FB; Hernandez AF; Fonarow GC
J Card Fail; 2022 Mar; 28(3):370-384. PubMed ID: 34793971
[TBL] [Abstract][Full Text] [Related]
10. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy.
Okumura N; Jhund PS; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Solomon SD; Packer M; McMurray JJ;
Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27618854
[TBL] [Abstract][Full Text] [Related]
11. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
[TBL] [Abstract][Full Text] [Related]
12. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy.
Malgie J; Clephas PRD; Brunner-La Rocca HP; de Boer RA; Brugts JJ
Heart Fail Rev; 2023 Sep; 28(5):1221-1234. PubMed ID: 37311917
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Limitations to Optimization of Guideline-Directed Medical Therapy in Heart Failure From the GUIDE-IT Trial: A Secondary Analysis of a Randomized Clinical Trial.
Fiuzat M; Ezekowitz J; Alemayehu W; Westerhout CM; Sbolli M; Cani D; Whellan DJ; Ahmad T; Adams K; Piña IL; Patel CB; Anstrom KJ; Cooper LS; Mark D; Leifer ES; Felker GM; Januzzi JL; O'Connor CM
JAMA Cardiol; 2020 Jul; 5(7):757-764. PubMed ID: 32319999
[TBL] [Abstract][Full Text] [Related]
14. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial.
Verma S; Dhingra NK; Butler J; Anker SD; Ferreira JP; Filippatos G; Januzzi JL; Lam CSP; Sattar N; Peil B; Nordaby M; Brueckmann M; Pocock SJ; Zannad F; Packer M;
Lancet Diabetes Endocrinol; 2022 Jan; 10(1):35-45. PubMed ID: 34861154
[TBL] [Abstract][Full Text] [Related]
15. Guideline-Directed Medical Therapy in Newly Diagnosed Heart Failure With Reduced Ejection Fraction in the Community.
Dunlay SM; Killian JM; Roger VL; Schulte PJ; Blecker SB; Savitz ST; Redfield MM
J Card Fail; 2022 Oct; 28(10):1500-1508. PubMed ID: 35902033
[TBL] [Abstract][Full Text] [Related]
16. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
[TBL] [Abstract][Full Text] [Related]
17. Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden).
Savarese G; Bodegard J; Norhammar A; Sartipy P; Thuresson M; Cowie MR; Fonarow GC; Vaduganathan M; Coats AJS
Eur J Heart Fail; 2021 Sep; 23(9):1499-1511. PubMed ID: 34132001
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of Quality of Care for US Veterans With Recent-Onset Heart Failure With Reduced Ejection Fraction.
Sandhu AT; Kohsaka S; Turakhia MP; Lewis EF; Heidenreich PA
JAMA Cardiol; 2022 Feb; 7(2):130-139. PubMed ID: 34757380
[TBL] [Abstract][Full Text] [Related]
19. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the Usage and Dosing of Guideline-Directed Medical Therapy for Heart Failure With Reduced Ejection Fraction Patients in Clinical Practice.
Smith KV; Dunning JR; Fischer CM; MacLean TE; Bosque-Hamilton JW; Fera LE; Grant JY; Zelle DJ; Matta L; Gaziano TA; MacRae CA; Scirica BM; Desai AS
J Pharm Pract; 2022 Oct; 35(5):747-751. PubMed ID: 33813934
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
